Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence.
Research was published online in the Journal of Medicinal Chemistry.
The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.
“Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions,” said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar’s Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. “We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors.”
The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.
“This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma,” said Hu. “Therefore, we are very interested in advancing them to the clinic.”
In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be “turned on” and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.
The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Pan-cancer mapping of differential protein-protein interactionson February 24, 2020 at 6:49 am
We also identified candidate protein modules with high diagnostic and/or prognostic performance, which might be useful in understanding tumorigenesis, development of novel diagnostic tools, and ...
- A single-dose HPV vaccine would have a big impact on cancer preventionon February 24, 2020 at 6:32 am
The body’s immune system usually clears out an HPV infection. But the virus persists in some people, causing HPV-related cancers in more than 600,000 men and women worldwide each year, the majority of ...
- Towson senior plans to shave her head for children’s cancer charityon February 24, 2020 at 5:00 am
It’s because of those two factors — her daughter’s surgery and the death of the other child — that Cripes says she intends to shave her head as part of a fundraiser for the St. Baldrick’s Foundation, ...
- Cancer Organoids Revolutionizing Cancer Drug Research Development and Mapping the Basic Cancer Treatment Necessityon February 24, 2020 at 12:14 am
26.1.2 Clinical Trial – Patient-Derived Organoid Model & Circulating Tumor Cell for Treatment Responses of Lung Cancer 26.1.3 Clinical Trial – Drug Sensitivity Correlation between Patient-Derived ...
- UCI makes tremendous strides in prevention, early detection and treatment of canceron February 23, 2020 at 8:43 am
... clinicians and researchers from more than 32 departments across six schools at UCI Is one of 51 National Cancer Institute-designated comprehensive cancer centers in the country Has treatment ...
- This Entrepreneur Is Changing the Face Of Cancer Treatment In Indiaon February 22, 2020 at 5:14 am
Breast cancer is the most common cancer in women in India. Accounting for 25-32 per cent of all cancers in women, the mortality rate post-treatment is 60 per cent, compared to as much as 89 per cent ...
- When Treating Women With Ovarian Cancer, Gynecologic Oncologist Emphasizes Openness And Dedication Throughout Journeyon February 21, 2020 at 1:51 pm
For women living with ovarian cancer, receiving treatment from a gynecologic oncologist can simplify care and provide a sense of familiarity with their treatment teams.
- Oral Cancer Treatment Market Healthcare, Clinical Reviews, Survey Reports 2019on February 21, 2020 at 3:51 am
The Global Oral Cancer Treatment Market Report provides a complete analysis of the market. The Report focuses on manufacturers, suppliers, segmentation according to the application, major players, ...
- Lung Cancer Treatment Drugs Market Insight, In-deep Analysis And Experts Review Report 2019-2025on February 21, 2020 at 3:50 am
The Global Lung Cancer Treatment Drugs Market Report provides a complete analysis of the market. The Report focuses on manufacturers, suppliers, segmentation according to the application, major ...
- Fertility treatment to help cancer patientson February 20, 2020 at 7:28 pm
Watch "Researchers giving cancer patients who wish to have a baby a new sense of hope", a CBSN video on CBSNews.com. View more CBSN videos and watch CBSN, a live news stream featuring original CBS ...
via Bing News